NORTH CHICAGO, November 19, 2026 — AbbVie has licensed a bispecific antibody platform from Germany-based DISCO Pharmaceuticals in a deal worth up to $2.54 billion, adding a precision oncology engine as the company builds its post-Humira growth strategy. The agreement gives AbbVie exclusive rights to develop and commercialize AND-gated bispecific therapeutics for solid tumors, with DISCO leading early research and discovery.
Deal Structure and Financial Terms
The licensing agreement includes a $40 million upfront payment to DISCO, up to $2.5 billion in potential milestone payments, and tiered royalties on worldwide net sales of any resulting products. DISCO will lead all research and discovery efforts, while AbbVie retains exclusive licensing rights to selected programs for subsequent development and commercialization. The partnership marks DISCO’s second major pharmaceutical collaboration in 2026, following a January deal with Amgen valued at up to $618 million.
How AND-Gated Bispecifics Work and Why They Matter for Solid Tumors
AND-gated bispecific antibodies are engineered to recognize cancer cells only when two target proteins are present simultaneously on the cell surface. This dual-targeting mechanism is designed to limit harm to healthy tissue that may express only one of the two proteins, a longstanding challenge in solid tumor therapy. The DISCO platform maps novel cell surface targets to develop targeted modalities including antibody-drug conjugates and T cell engagers. Early findings suggest this logic-gated approach could improve the therapeutic window for cancers where single-target therapies have struggled with on-target, off-tumor toxicity.
AbbVie’s Post-Humira Revenue Trajectory
AbbVie’s immunology franchise continues to absorb the impact of Humira’s U.S. patent expiry in 2023. In the third quarter of 2026, Humira sales declined 30.6% year-over-year to $683 million due to biosimilar competition. Meanwhile, Skyrizi sales reached $5.8 billion, up 22.9%, and Rinvoq revenues hit $2.7 billion, up 24.3%. Combined immunology revenues grew 16.6% to approximately $9.2 billion, accounting for nearly 53% of total revenues. The company has raised its 2026 sales forecasts to $21.8 billion for Skyrizi and $10.3 billion for Rinvoq, with combined immunology revenues projected at approximately $34.9 billion.
Strategic Fit Alongside Existing Oncology Assets
The DISCO collaboration expands AbbVie’s early-stage oncology pipeline, which already includes commercialized therapies Elahere and Epkinly. Bispecific antibodies have attracted mounting interest from large drugmakers including Bristol Myers Squibb and Merck as the industry pursues new modalities for cancer care. AbbVie executives stated during the Q3 2026 earnings call that the company has plenty of capacity for mergers, acquisitions, and licensing deals. The company most recently committed $100 million upfront plus $1.37 billion in potential milestones for an EP4 receptor agonist program from Nxera Pharma targeting inflammatory bowel disease.
Platform Validation and Next Steps
The Amgen partnership in January provided an early validation of DISCO’s platform technology. Under the AbbVie agreement, DISCO will continue to lead research and discovery, with AbbVie exercising options on selected programs to advance into clinical development. Milestone payments will be triggered as programs progress through predefined research, development, and regulatory stages. Patients should talk to their doctor or oncologist about current treatment options and whether clinical trial participation may be appropriate for their situation.
Sources
- AbbVie
- ‘More than a building’: How the AbbVie Foundation Cancer Pavilion is designed to support clinical trials, research – UChicago Medicine
- How Did AbbVie's Immunology Franchise Fare in Q3?
- AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal
- Is AbbVie Stock Really Expensive?
- Dividend King AbbVie Strikes Up to $2.54B DISCO Pharma Pact for Next-Gen Precision Cancer Therapies
Photo: Emmanuelle Alaluf (CC BY 4.0)





